This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of intravesical ozone therapy in 60 patients with interstitial cystitis (IC). Participants were assigned to ozone therapy, placebo, or standard care groups for 3 weeks, with follow-up at 6 weeks. The primary outcome was the change in O'Leary-Sant ICSI score. Secondary outcomes included VAS pain score, SF-36 physical health, and urinary frequency.

Patients received either 50 mL ozonated saline (20-40 µg/mL), normal saline (placebo), or continued standard care twice weekly for 3 weeks. Assessments were conducted at baseline, week 3, and week 6. The study aimed to determine if ozone therapy reduces interstitial cystitis symptoms compared to placebo and standard care.

Inclusion Criteria:

• Age 18-65 years
• Histopathologically or clinically confirmed IC (per AUA guidelines)
• Symptoms for at least 6 months
• Willing to provide informed consent

Exclusion Criteria:

• Active urinary tract infection
• Bladder malignancy
• Pregnancy or breastfeeding
• Known ozone allergy
• Intravesical therapy within 3 months
• G6PD deficiency

Individual participant data will not be shared due to privacy concerns and the absence of a data-sharing agreement.